Related Experiment Videos
Inhibition of tumor growth by plasminogen-related protein-B
V O Lewis1, M S O'Reilly, M Gehrmann
1Orthopaedic Research Laboratories, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA. volewis@mail.mdanderson.org
Background:
Various fragments of the fibrinolytic protein plasminogen can act as antiangiogenic factors and inhibit the growth of primary and metastatic tumors in mice. Plasminogen-related gene-B encodes a putative 9 kDa protein virtually identical to the plasminogen N-terminal activation peptide, a 77-amino acid motif that is liberated from the parent plasminogen molecule during conversion to the serine proteinase plasmin. Previous data have documented enhanced transcription of plasminogen-related gene-B in neoplastic tissues.
Materials And Methods:
We have tested the effects of recombinant versions of plasminogen-related protein-B and the plasminogen N-terminal activation peptide on the growth of tumors in mice, employing murine tumor cell lines implanted subcutaneously.
Results:
The recombinant plasminogen-related protein-B significantly inhibited the growth of primary tumors in mice, while recombinant plasminogen N-terminal activation peptide elicited only a slight inhibition of tumor growth.
Conclusion:
These data suggest that plasminogen-related protein-B may have utility as a novel cancer therapeutic.
Insights
Plasminogen-related protein-B effectively inhibits primary tumor growth in mice, showing potential as a novel cancer therapeutic. This finding highlights its anti-tumorigenic properties for future development.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Plasminogen fragments exhibit antiangiogenic properties, inhibiting tumor growth.
- Plasminogen-related gene-B encodes a protein similar to the plasminogen N-terminal activation peptide.
- Plasminogen-related gene-B shows increased transcription in neoplastic tissues.
Purpose of the Study:
- To evaluate the anti-tumorigenic effects of recombinant plasminogen-related protein-B.
- To compare the efficacy of plasminogen-related protein-B with the plasminogen N-terminal activation peptide in inhibiting tumor growth.
Main Methods:
- Utilized recombinant versions of plasminogen-related protein-B and plasminogen N-terminal activation peptide.
- Assessed tumor growth inhibition in mice with subcutaneously implanted murine tumor cell lines.
Main Results:
- Recombinant plasminogen-related protein-B significantly inhibited primary tumor growth in mice.
- Recombinant plasminogen N-terminal activation peptide demonstrated only a slight inhibition of tumor growth.
Conclusions:
- Plasminogen-related protein-B demonstrates significant anti-tumorigenic activity.
- Plasminogen-related protein-B holds promise as a novel therapeutic agent for cancer treatment.